Cargando…

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

Detalles Bibliográficos
Autores principales:	Sekeres, M A, Swern, A S, Fenaux, P, Greenberg, P L, Sanz, G F, Bennett, J M, Dreyfus, F, List, A F, Li, J S, Sugrue, M M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219467/ https://www.ncbi.nlm.nih.gov/pubmed/25171203 http://dx.doi.org/10.1038/bcj.2014.62

Ejemplares similares

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2014)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2015)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash
por: Weiss, Lilia, et al.
Publicado: (2015)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
por: Wu, Junying, et al.
Publicado: (2022)

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
por: McDaniel, Jessica M., et al.
Publicado: (2011)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
por: Kuendgen, A, et al.
Publicado: (2013)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome
por: Ma, Jiale, et al.
Publicado: (2023)

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
por: Pardanani, A, et al.
Publicado: (2012)

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
por: Platzbecker, U, et al.
Publicado: (2014)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score
por: Silzle, Tobias, et al.
Publicado: (2023)

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2011)

High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies
por: Wan, Ziqi, et al.
Publicado: (2021)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
por: Sugimoto, Yuka, et al.
Publicado: (2012)

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
por: Ma, Xiaomei, et al.
Publicado: (2018)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
por: Scheid, C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b6bvvqaou5d9nuofsn1sni2phi